Critical Survey: VolitionRx (NYSE:VNRX) vs. Oruka Therapeutics (NASDAQ:ORKA)

VolitionRx (NYSE:VNRX) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for VolitionRx and Oruka Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VolitionRx	0	1	1	0	2.50
Oruka Therapeutics	0	0	6	2	3.25

VolitionRx currently has a consensus price target of $2.50, indicating a potential upside of 259.53%. Oruka Therapeutics has a consensus price target of $43.17, indicating a potential upside of 54.22%. Given VolitionRx’s higher possible upside, research analysts clearly believe VolitionRx is more favorable than Oruka Therapeutics.

Risk and Volatility

VolitionRx has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.

Insider and Institutional Ownership

8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 12.8% of VolitionRx shares are owned by insiders. Comparatively, 30.9% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares VolitionRx and Oruka Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VolitionRx	-3,318.42%	N/A	-165.21%
Oruka Therapeutics	N/A	-20.18%	-19.51%

Earnings & Valuation

This table compares VolitionRx and Oruka Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VolitionRx	$976,516.00	59.05	-$35.32 million	($0.46)	-1.51
Oruka Therapeutics	N/A	N/A	-$5.34 million	($6.00)	-4.66

Oruka Therapeutics has lower revenue, but higher earnings than VolitionRx. Oruka Therapeutics is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.

Summary

Oruka Therapeutics beats VolitionRx on 8 of the 14 factors compared between the two stocks.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.